Requiring institutions to inform participants who have completed therapy on SWOG-8892 (RT +/- cisplatin for nasopharyngeal cancer) about early study closure: right idea, wrong patients.
Amdur
R J
RJ
Bankert
E
E
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D003131:Combined Modality Therapy; D006801:Humans; D015337:Multicenter Studies as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D010349:Patient Compliance; D011367:Professional Staff Committees / Q000331:legislation & jurisprudence* / Q000592:standards; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use; D014342:Truth Disclosure; D014481:United States
D000970:Antineoplastic Agents; D011838:Radiation-Sensitizing Agents; D002945:Cisplatin